Non-steroidal Anti-inflammatory Drugs Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 26.83 Billion |
| Market Size (2029) | USD 39.22 Billion |
| CAGR (2024 - 2029) | 7.89 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Non-steroidal Anti-inflammatory Drugs Market Analysis
The Non-steroidal Anti-Inflammatory Drugs Market size is estimated at USD 26.83 billion in 2024, and is expected to reach USD 39.22 billion by 2029, growing at a CAGR of 7.89% during the forecast period (2024-2029).
The increasing burden of chronic pain and inflammatory diseases globally is expected to boost the market's growth during the forecast period, as NSAIDs are widely used in their treatment and management. In addition, investment in research and development by pharmaceutical companies to develop advanced NSAIDs is likely to contribute to market expansion.
The high prevalence of low back pain, which is expected to increase in the coming years, is anticipated to lead to a rise in the usage of NSAIDs during the forecast period. For instance, according to data published by the WHO in December 2023, projections estimate that 843 million individuals will experience low back pain by 2050, with the most significant increases expected in Africa and Asia due to their expanding populations and increasing life expectancies. This high number of low back pain cases increases the usage of NSAIDs and is expected to contribute to the growth of the market during the forecast period.
Musculoskeletal conditions such as arthritis and back pain are some of the leading contributors to disability worldwide. For instance, according to data published by the National Center for Health Statistics in February 2024, the age-adjusted prevalence of arthritis in adults aged 18 and older in the United States was reported to be 18.9% in 2022, which is significantly high. Therefore, the high burden of musculoskeletal disorders is likely to lead to a growing demand for pain management drugs such as NSAIDs, contributing to the market's growth during the forecast period.
Also, the growing awareness among the public through awareness initiatives likely increases the usage of aspirin as it is widely used in cardiovascular diseases. For instance, in February 2023, Huma Therapeutics Limited and Bayer entered a partnership to develop the Bayer aspirin heart risk assessment online tool to raise awareness of heart health and its risk factors. Hence, understanding heart health and its risk factors helps increase aspirin usage in ongoing health management. Thus, this growing awareness is expected to drive market growth due to the proper usage of NSAIDs by the public.
Therefore, the high burden of pain cases due to musculoskeletal conditions and increasing awareness are likely to drive market growth during the forecast period. However, the side effects caused by the use of NSAIDs are expected to restrain the market's growth during the forecast period.
Non-steroidal Anti-inflammatory Drugs Market Trends
The Arthritis Segment is Expected to Grow Faster and Dominate the Market During the Forecast Period
Arthritis is a health condition that encompasses various conditions characterized by inflammation of the joints. It can lead to pain, swelling, stiffness, and reduced joint mobility. The market for non-steroidal anti-inflammatory drugs (NSAIDs) is expected to grow due to the increasing incidence of arthritis, as these drugs are commonly used in patients with chronic inflammatory arthritis. NSAIDs effectively reduce inflammation and pain due to their ability to inhibit prostaglandins' biosynthesis at the cyclooxygenase enzyme level.
The arthritis segment is expected to hold a significant share during the forecast period due to the high burden of arthritis among the population and the increasing demand for effective pain management drugs, including NSAIDs. For instance, according to the data published by the Australian Bureau of Statistics in December 2023, 3.7 million cases were reported in 2022 in Australia, which includes 57% of osteoarthritis, 13.9% of rheumatoid arthritis, and 37.3% of other arthritis types. This shows that the rising prevalence of arthritis will likely increase the usage of NSAIDs and boost segment growth during the study period.
Severe arthritis can limit physical activity and is directly associated with obesity, cardiovascular disease, diabetes, and other functional limitations. The older population's increased susceptibility to arthritis due to age-related decline in bone density and weak joint ligaments is also expected to contribute to segment expansion.
Several NSAID drugs are available in the market, with more being approved to meet the growing demand for arthritis pain management, contributing to segment growth. For instance, in March 2024, Endo International PLC and Par Pharmaceutical Inc. launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's DUEXIS. This combination medication is used to relieve the signs and symptoms of arthritis while decreasing the risk of developing ulcers in the stomach. Thus, the factors mentioned above are expected to increase the demand for NSAIDS for arthritis and are likely to drive the growth of the segment during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is poised to dominate the NSAID (non-steroidal anti-inflammatory drugs) market, holding a significant share during the forecast period. The increasing demand for effective drugs for pain relief and growing awareness among the North American population are key factors driving the market's growth in this region. In addition, North America, particularly the United States and Canada, has a significant aging population. As people age, the prevalence of chronic conditions such as arthritis, which often require NSAIDs for pain and inflammation management, increases. This demographic shift drives demand for NSAIDs.
Chronic pain-causing disorders such as migraine are prevalent among the North American population, which is expected to drive the market. For example, according to data published by the Ministry of Health in Mexico in September 2023, it was reported that in 2022, 20 million people suffered from migraine, which is one of the most common disabling diseases in Mexico. This demonstrates the high prevalence of migraines, leading to an increased demand for NSAIDs for pain management, thus driving market growth in the region during the study period.
Market players in North America continuously focus on strategic activities such as increasing the production of NSAIDs and product approvals to tackle the pain of various conditions. For instance, in November 2023, Scilex Holding Company planned to increase the manufacturing of ELYXYB (celecoxib oral solution) to meet its rising demand and increased stocking needs in its distribution center. These activities increase the availability of NSAIDs, which is expected to boost the region's market growth during the forecast period.
Therefore, the high burden of pain conditions, along with the market player strategies, is likely to increase the usage of NSAIDs, and the segment is expected to grow significantly during the forecast period.
Non-steroidal Anti-inflammatory Drugs Industry Overview
The non-steroidal anti-inflammatory drugs (NSAIDs) market is fragmented, with several players around the globe. In terms of market share, few of the major players now dominate the market. With the increase in research and development activity, many regional players are expected to contribute to the NSAIDs market during the forecast period. Some of the key players in the market are Pfizer Inc., Haleon PLC, Johnson & Johnson, Bayer AG, Sanofi SA, Horizon Therapeutics PLC, Sun Pharmaceutical Industries Ltd, and Reckitt Benckiser Group PLC.
Non-steroidal Anti-inflammatory Drugs Market Leaders
-
Pfizer Inc.
-
Johnson & Johnson
-
Bayer AG
-
Sanofi S.A.
-
Haleon plc
*Disclaimer: Major Players sorted in no particular order
Non-steroidal Anti-inflammatory Drugs Market News
- April 2024: Glenmark Pharmaceuticals Ltd (Glenmark) received approval from the United States Food and Drug Administration (US FDA) for acetaminophen and ibuprofen tablets, 250 mg/125 mg (OTC).
- December 2023: Scilex Holding Company filed a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB for acute treatment of migraine with or without aura in Canada.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Chronic Pain and Inflammation
4.2.2 Preference of NSAIDs Over Other Class of Pain Relievers
4.3 Market Restraints
4.3.1 High Cost of Drug Development and Launches
4.3.2 Side Effects of NSAIDs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Route of Administration
5.1.1 Oral
5.1.2 Parenteral
5.1.3 Topical
5.1.4 Other Routes of Administration (Rectal, Nasal, etc.)
5.2 By Application
5.2.1 Arthritis
5.2.2 Migraine
5.2.3 Ophthalmic Diseases
5.2.4 Other Applications (Fever, Dysmenorrhea, etc.)
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others Distribution Channels (Wholesale Pharmacies, Supermarkets, etc.)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Haleon PLC
6.1.3 Johnson & Johnson
6.1.4 Bayer AG
6.1.5 Sanofi SA
6.1.6 Horizon Therapeutics PLC
6.1.7 Sun Pharmaceutical Industries Ltd
6.1.8 Iroko Pharmaceuticals Inc.
6.1.9 Reckitt Benckiser Group PLC
6.1.10 Assertio Therapeutics Inc.
6.1.11 Zyla Life Sciences
6.1.12 Perrigo Company
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Non-steroidal Anti-inflammatory Drugs Industry Segmentation
As per the report's scope, non-steroidal anti-inflammatory drugs (NSAIDs) are medications that reduce pain, decrease fever, prevent blood clots, and decrease inflammation in higher doses. NSAIDs inhibit enzymes in the body that produce prostaglandins, which are naturally occurring fatty acids that contribute to pain and inflammation.
The non-steroidal anti-inflammatory drugs (NSAIDs) market is segmented by route of administration, application, distribution channel, and geography. By route of administration, the market is segmented into oral, parenteral, topical, and other routes of administration. By application, the market is segmented into arthritis, migraine, ophthalmic diseases, and other applications. The other applications include fever and blood clots. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecasts in value (USD) for the above segments.
| By Route of Administration | |
| Oral | |
| Parenteral | |
| Topical | |
| Other Routes of Administration (Rectal, Nasal, etc.) |
| By Application | |
| Arthritis | |
| Migraine | |
| Ophthalmic Diseases | |
| Other Applications (Fever, Dysmenorrhea, etc.) |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Others Distribution Channels (Wholesale Pharmacies, Supermarkets, etc.) |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Research FAQs
How big is the Non-steroidal Anti-Inflammatory Drugs Market?
The Non-steroidal Anti-Inflammatory Drugs Market size is expected to reach USD 26.83 billion in 2024 and grow at a CAGR of 7.89% to reach USD 39.22 billion by 2029.
What is the current Non-steroidal Anti-Inflammatory Drugs Market size?
In 2024, the Non-steroidal Anti-Inflammatory Drugs Market size is expected to reach USD 26.83 billion.
Who are the key players in Non-steroidal Anti-Inflammatory Drugs Market?
Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A. and Haleon plc are the major companies operating in the Non-steroidal Anti-Inflammatory Drugs Market.
Which is the fastest growing region in Non-steroidal Anti-Inflammatory Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Non-steroidal Anti-Inflammatory Drugs Market?
In 2024, the North America accounts for the largest market share in Non-steroidal Anti-Inflammatory Drugs Market.
What years does this Non-steroidal Anti-Inflammatory Drugs Market cover, and what was the market size in 2023?
In 2023, the Non-steroidal Anti-Inflammatory Drugs Market size was estimated at USD 24.71 billion. The report covers the Non-steroidal Anti-Inflammatory Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Non-steroidal Anti-Inflammatory Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
NSAIDs Industry Report
Statistics for the 2024 NSAIDs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. NSAIDs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
